Literature DB >> 10971300

The clinical impact of different assays for prostate specific antigen.

A Semjonow1, G De Angelis, F Oberpenning, H P Schmid, B Brandt, L Hertle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10971300     DOI： 10.1046/j.1464-410x.2000.00858.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  5 in total

1.  [PSA 2010--the beginning of a new era in early detection of prostate cancer].

Authors:  C Börgermann; M Sieverding; P Fornara; M Graefen; P Hammerer; A Semjonow; F Schröder; H Rübben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  Current usefulness of free/total PSA ratio in the diagnosis of prostate cancer at an early stage.

Authors:  Christian Pfister; Jean-Pierre Basuyau
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

3.  Inadequate Reporting of Analytical Characteristics of Biomarkers Used in Clinical Research: A Threat to Interpretation and Replication of Study Findings.

Authors:  Qian Sun; Kerry J Welsh; David E Bruns; David B Sacks; Zhen Zhao
Journal:  Clin Chem       Date:  2019-10-31       Impact factor: 8.327

4.  Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity.

Authors:  Carsten Stephan; Nicola Büker; Henning Cammann; Hellmuth-Alexander Meyer; Michael Lein; Klaus Jung
Journal:  BMC Urol       Date:  2008-09-02       Impact factor: 2.264

5.  Evaluation of a rapid quantitative determination method of PSA concentration with gold immunochromatographic strips.

Authors:  Cheng-Ching Wu; Hung-Yu Lin; Chao-Ping Wang; Li-Fen Lu; Teng-Hung Yu; Wei-Chin Hung; Jer-Yiing Houng; Fu-Mei Chung; Yau-Jiunn Lee; Jin-Jia Hu
Journal:  BMC Urol       Date:  2015-11-03       Impact factor: 2.264
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.